Products Esomeprazole + Placebo
Esomeprazole + Placebo Phase 3 Completed 📈 Rising Feb 1, 2010 → Nov 1, 2011
About Esomeprazole + Placebo Esomeprazole + Placebo is a phase 3 stage product being developed by AstraZeneca for Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT01069939. Target conditions include Prevention.
Clinical Trials (7) NCT ID Phase Status Start Completion Indication NCT01069939 Phase 3 Completed Feb 1, 2010 Nov 1, 2011 Prevention NCT00660660 Approved Completed Apr 1, 2008 Jul 1, 2008 Gastroesophageal Reflux Disease NCT00542789 Phase 3 Completed Aug 1, 2007 Feb 1, 2009 Gastric Ulcer NCT00287339 Approved Completed Sep 1, 2005 Sep 1, 2008 Cough NCT00745849 Pre-clinical Completed Jun 1, 2005 Mar 1, 2008 Vasomotor Rhinitis NCT00628953 Phase 2 Completed Oct 1, 2002 Apr 1, 2004 Asthma NCT00628667 Approved Completed Feb 1, 2002 Mar 1, 2003 Chronic Posterior Laryngitis (CPL)
Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 PCV15 Merck Pre-clinical Raltegravir Merck Approved RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 Zostavax Merck Phase 3 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-coated mycophenolate sodium Novartis Phase 3 Meningococcal C conjugate vaccine Novartis Approved rMenB+OMV NZ Novartis Phase 3 Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 Meningococcal C Conjugate Vaccine Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from AstraZeneca